| Literature DB >> 35672900 |
Emma I Kopra1, Jason A Ferris2, James J Rucker1,3, Benjamin McClure4, Allan H Young1,3, Caroline S Copeland5,6, Adam R Winstock7,8.
Abstract
BACKGROUND: Recreational lysergic acid diethylamide (LSD) use is growing in popularity amid increasing research interest on psychedelics and their possible therapeutic potential yet; the potent psychotropic effects of LSD may result in adverse reactions and behaviour. AIMS: This study aimed to investigate the 12-month incidence and nature of LSD-related adverse experiences resulting in emergency medical treatment (EMT) seeking in an international sample of people reporting LSD use.Entities:
Keywords: Adverse effects; LSD; psychedelics; safety
Mesh:
Substances:
Year: 2022 PMID: 35672900 PMCID: PMC9353972 DOI: 10.1177/02698811221099650
Source DB: PubMed Journal: J Psychopharmacol ISSN: 0269-8811 Impact factor: 4.562
Demographic profile of past-year LSD users.
|
| Valid %
| |
|---|---|---|
| 13,769 | 51.8
| |
|
| ||
| <25 | 8802 | 63.9 |
| 25–34 | 3874 | 28.1 |
| 35+ | 1093 | 7.9 |
|
| ||
| Male | 10,967 | 79.6 |
| Female | 2802 | 20.4 |
|
| ||
| Germany | 2719 | 19.7 |
| USA | 2703 | 19.6 |
| UK | 1127 | 8.2 |
| Denmark | 1039 | 7.5 |
| Canada | 793 | 5.8 |
| Australia | 693 | 5.0 |
| Other | 4695 | 34.1 |
|
| ||
| White | 6959 | 84.8 |
| Hispanic/Latino | 533 | 6.5 |
| Mixed | 384 | 4.7 |
| Other | 332 | 4.0 |
|
| ||
| None | 6148 | 73.8 |
| Yes
| 2187 | 26.2 |
| Depression | 1583 | 19.0 |
| Anxiety | 1120 | 13.4 |
| ADHD | 526 | 6.3 |
| Bipolar | 216 | 2.6 |
| Psychosis | 98 | 1.2 |
| Other | 396 | 4.8 |
|
| ||
| Past month users | 4590 | 33.3 |
| Past year novel users | 4271 | 41.6 |
| Median days past year use (IQR) | 2 | 1–5 |
Percentage when missing data excluded.
Proportion of lifetime users.
Those with a diagnosis were able to tick more than one diagnosis, hence the total number of these being larger than the number of respondents responding ‘Yes’.
Figure 1.Question response flow chart.
Self-reported symptoms.
|
| % | |
|---|---|---|
| Anxiety/panic | 71 | 69.6 |
| Confusion | 66 | 64.7 |
| Paranoia/suspiciousness | 50 | 49.0 |
| Seeing/hearing things | 46 | 45.1 |
| Extreme agitation | 40 | 39.2 |
| Memory loss | 29 | 28.4 |
| Extreme sweating | 27 | 26.5 |
| Palpitations | 26 | 25.5 |
| Very low mood in days afterwards | 23 | 22.5 |
| Thoughts or acts of self-harm | 21 | 20.6 |
| Difficulty breathing | 21 | 20.6 |
| Aggression/violence | 18 | 17.6 |
| Nausea/vomiting | 18 | 17.6 |
| Accident/trauma | 17 | 16.7 |
| Other | 16 | 15.7 |
| Chest pain | 13 | 12.7 |
| Fits/seizures | 13 | 12.7 |
| Passed out/unconscious | 12 | 11.8 |
| Headache | 7 | 6.9 |
| Bladder/kidney problems | 4 | 3.9 |
Figure 2.Time to recovery (NR = not recovered).
Other substances used preceding the incident.
|
| % | |
|---|---|---|
| Cannabis | 51 | 50.0 |
| Alcohol | 24 | 23.5 |
| MDMA | 12 | 11.8 |
| Benzodiazepines | 6 | 5.9 |
| Cocaine | 5 | 4.9 |
| Amphetamine | 4 | 3.9 |
| Other | 4 | 3.9 |
| NPS | 3 | 2.9 |
| Ketamine | 2 | 2.0 |
| 2C-B | 1 | 1.0 |
| Mephedrone | 1 | 1.0 |
| Opioids | 1 | 1.0 |
| Nothing else | 33 | 32.4 |
MDMA = 3,4-Methyl enedioxy methamphetamine; NPS = New psychoactive substances.
Figure 3.Self-reported reasons for the incident.